MedTrace Logo

Seeing to Learn in Sierra Leone

NCT06065631 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1821

Last updated 2026-01-20

No results posted yet for this study

Summary

The main objective of the Sierra Leone Sees to Learn (SL2) trial is to assess the educational impact of providing free eyeglasses to students aged 9-20 years with uncorrected refractive error in Sierra Leone. The procedures include baseline questionnaires and educational assessments to collect data on students and schools, and then the provision of free eyeglasses to students who have uncorrected (or undercorrected) refractive error (URE). The questionnaires and student assessments will take 1-2 hours. The duration of the study timeframe is one school year. The end-line questionnaires and student assessments will be administered at the end of the school year.

Conditions

  • Refractive Errors

Interventions

DEVICE

Eyeglasses

Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.

OTHER

Prescription slip

Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial

Sponsors & Collaborators

  • Innovations for Poverty Action

    collaborator OTHER

  • Peek Vision

    collaborator UNKNOWN

  • Vision Action

    collaborator UNKNOWN

  • University of Minnesota

    lead OTHER

Principal Investigators

  • Nathan Congdon, MD · Queen's University, Belfast

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Sierra Leone

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06065631 on ClinicalTrials.gov